Published in Cancer Gene Ther on April 01, 2005
Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer Res (2009) 1.47
Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Res (2008) 1.24
"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther (2009) 1.20
Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther (2008) 1.12
Mathematical modeling of herpes simplex virus distribution in solid tumors: implications for cancer gene therapy. Clin Cancer Res (2009) 1.05
Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol (2012) 1.03
Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther (2009) 0.99
Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice. PLoS One (2010) 0.97
CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV. Pediatr Blood Cancer (2012) 0.90
The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors. Cancer Gene Ther (2013) 0.85
Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity. Mol Ther Oncolytics (2015) 0.85
Localized in vivo activation of a photoactivatable doxorubicin prodrug in deep tumor tissue. Photochem Photobiol (2013) 0.84
VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells. Mol Ther (2013) 0.83
ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN. Drugs Future (2010) 0.82
Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy. Expert Opin Investig Drugs (2008) 0.81
Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children. Mol Ther Oncolytics (2015) 0.78
Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors. Ann Oncol (2015) 0.78
Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma. Transl Oncol (2016) 0.75
Comparative protein profiling of B16 mouse melanoma cells susceptible and non-susceptible to alphavirus infection: Effect of the tumor microenvironment. Cancer Biol Ther (2016) 0.75
Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002. Mol Ther Oncolytics (2017) 0.75
TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma. Mol Ther Oncolytics (2017) 0.75
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest (2012) 1.83
Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer Res (2009) 1.47
Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther (2008) 1.44
Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One (2009) 1.40
The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study. J Pediatr Surg (2005) 1.39
Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res (2006) 1.32
Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein. Clin Cancer Res (2009) 1.26
Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res (2008) 1.24
"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther (2009) 1.20
Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer (2009) 1.19
Targeting cancer-initiating cells with oncolytic viruses. Mol Ther (2009) 1.18
Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther (2007) 1.15
Statistical issues in longitudinal data analysis for treatment efficacy studies in the biomedical sciences. Mol Ther (2010) 1.14
Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther (2008) 1.12
Saposin C coupled lipid nanovesicles enable cancer-selective optical and magnetic resonance imaging. Mol Imaging Biol (2011) 1.08
Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol (2012) 1.03
Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatr Blood Cancer (2011) 1.02
Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr Blood Cancer (2005) 1.01
Oncolytic virotherapy reaches adolescence. Pediatr Blood Cancer (2010) 0.99
A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells. Cancer Res (2013) 0.99
Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants. Pediatr Blood Cancer (2006) 0.98
Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target. Clin Cancer Res (2012) 0.98
Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clin Cancer Res (2010) 0.97
Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J Pediatr Hematol Oncol (2003) 0.96
Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses. J Pediatr Hematol Oncol (2002) 0.94
Differing approaches to experimental therapeutics: are we a world apart? Mol Ther (2012) 0.89
Cyclooxygenase-2 expression in pediatric sarcomas. Pediatr Dev Pathol (2002) 0.87
Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts. J Pediatr Hematol Oncol (2003) 0.87
Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma. Pediatr Blood Cancer (2014) 0.86
Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. Pediatr Blood Cancer (2014) 0.83
VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells. Mol Ther (2013) 0.83
EGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing's sarcoma model. J Surg Res (2011) 0.82
Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors. J Gene Med (2010) 0.82
Cancer screening by systemic administration of a gene delivery vector encoding tumor-selective secretable biomarker expression. PLoS One (2011) 0.80
Going back to class I: MHC and immunotherapies for childhood cancer. Pediatr Blood Cancer (2014) 0.80
In vivo regulation of TGF-β by R-Ras2 revealed through loss of the RasGAP protein NF1. Cancer Res (2012) 0.79
Women's experience of viewing the products of conception after an abortion. Contraception (2009) 0.79
A lab-on-a-chip for rapid blood separation and quantification of hematocrit and serum analytes. Lab Chip (2011) 0.78
Improving patient care: the use of a digital teaching file to enhance clinicians' access to the intellectual capital of interdepartmental conferences. AJR Am J Roentgenol (2004) 0.78
Ewing sarcoma family of tumors express adenovirus receptors and are susceptible to adenovirus-mediated oncolysis. J Pediatr Hematol Oncol (2002) 0.78
Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy. Pediatr Blood Cancer (2014) 0.78
Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. J Clin Invest (2015) 0.77
Adventitious mutations in clinical grade vectors: an issue to consider? Mol Ther (2006) 0.76
Adenovirus gene therapy for pediatric cancers: shall we gather at the liver? Pediatr Blood Cancer (2009) 0.75
Associations between DISC assessment and performance in obstetrics and gynecology residents. J Reprod Med (2011) 0.75
A young girl with hemolytic anemia and elevated hemoglobin F. Pediatr Blood Cancer (2005) 0.75
Emerging cancer-targeted therapies. Pediatr Clin North Am (2002) 0.75
Indiana University Health staffing model for neurotelemetry and epilepsy monitoring unit patient populations: Part 1. Neurodiagn J (2014) 0.75